{"filing":{"accession_number":"0001598599-26-000008","cik":"0001598599","ticker":"IPHYF","company_name":"Innate Pharma SA","form":"6-K","filing_date":"2026-07-21","report_date":null,"primary_document":"a2607216kincorporatediph1.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1598599/000159859926000008/a2607216kincorporatediph1.htm"},"events":[{"id":18924,"run_id":17024,"accession_number":"0001598599-26-000008","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces completion of enrollment in a Phase 1 dose-escalation study of IPH4502, a proprietary Nectin-4 ADC, with preliminary data expected by year-end. The disclosure reports a clinical development milestone—enrollment completion in 76 patients—and preliminary safety and efficacy observations (favorable safety profile with limited hematological toxicity, objective responses in multiple tumor types). This is a material operational/clinical milestone for a clinical-stage biotech company that would affect investor assessment of the company's pipeline progress and the drug candidate's potential, but it does not fit the specific event categories (not an earnings release, M\u0026A activity, executive change, impairment, or other named types). It is clearly operational/strategic in nature.","company_name":"Innate Pharma SA","ticker":"IPHYF","filing_date":"2026-07-21","form":"6-K","submitted_at":null,"items":[{"id":17881,"accession_number":"0001598599-26-000008","item_number":"EX-99.1","item_title":"a260721exhibit991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of enrollment in a Phase 1 dose-escalation study of IPH4502, a proprietary Nectin-4 ADC, with preliminary data expected by year-end. The disclosure reports a clinical development milestone—enrollment completion in 76 patients—and preliminary safety and efficacy observations (favorable safety profile with limited hematological toxicity, objective responses in multiple tumor types). This is a material operational/clinical milestone for a clinical-stage biotech company that would affect investor assessment of the company's pipeline progress and the drug candidate's potential, but it does not fit the specific event categories (not an earnings release, M\u0026A activity, executive change, impairment, or other named types). It is clearly operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T10:09:38.658932+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17881,"accession_number":"0001598599-26-000008","item_number":"EX-99.1","item_title":"a260721exhibit991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of enrollment in a Phase 1 dose-escalation study of IPH4502, a proprietary Nectin-4 ADC, with preliminary data expected by year-end. The disclosure reports a clinical development milestone—enrollment completion in 76 patients—and preliminary safety and efficacy observations (favorable safety profile with limited hematological toxicity, objective responses in multiple tumor types). This is a material operational/clinical milestone for a clinical-stage biotech company that would affect investor assessment of the company's pipeline progress and the drug candidate's potential, but it does not fit the specific event categories (not an earnings release, M\u0026A activity, executive change, impairment, or other named types). It is clearly operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T10:09:38.658932+00:00","company_name":"Innate Pharma SA","ticker":"IPHYF","filing_date":"2026-07-21"}]}